SpringWorks Therapeutics Statistics
Share Statistics
SpringWorks Therapeutics has 74.39M shares outstanding. The number of shares has increased by 3.07% in one year.
| Shares Outstanding | 74.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 65.87M |
| Failed to Deliver (FTD) Shares | 303 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 11.63M, so 15.63% of the outstanding shares have been sold short.
| Short Interest | 11.63M |
| Short % of Shares Out | 15.63% |
| Short % of Float | 17.67% |
| Short Ratio (days to cover) | 13.14 |
Valuation Ratios
The PE ratio is -7.09 and the forward PE ratio is -16.62.
| PE Ratio | -7.09 |
| Forward PE | -16.62 |
| PS Ratio | 422.99 |
| Forward PS | 7.5 |
| PB Ratio | 3.68 |
| P/FCF Ratio | -10.01 |
| PEG Ratio | n/a |
Enterprise Valuation
SpringWorks Therapeutics Inc. has an Enterprise Value (EV) of 2.14B.
| EV / Earnings | -6.57 |
| EV / Sales | 391.96 |
| EV / EBITDA | -6.25 |
| EV / EBIT | -6.22 |
| EV / FCF | -9.28 |
Financial Position
The company has a current ratio of 6.41, with a Debt / Equity ratio of 0.
| Current Ratio | 6.41 |
| Quick Ratio | 6.37 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.17 |
| Cash Flow / Debt | -209.99 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.52% and return on capital (ROIC) is -54.16%.
| Return on Equity (ROE) | -0.52% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -54.16% |
| Revenue Per Employee | 17.86K |
| Profits Per Employee | -1.07M |
| Employee Count | 305 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.14 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 12.92% in the last 52 weeks. The beta is 0.79, so SpringWorks Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.79 |
| 52-Week Price Change | 12.92% |
| 50-Day Moving Average | 34.61 |
| 200-Day Moving Average | 39.46 |
| Relative Strength Index (RSI) | 51.19 |
| Average Volume (20 Days) | 1.11M |
Income Statement
In the last 12 months, SpringWorks Therapeutics had revenue of $5.45M and earned -$325.10M in profits. Earnings per share was $-5.15.
| Revenue | 5.45M |
| Gross Profit | 5.03M |
| Operating Income | -343.01M |
| Net Income | -325.10M |
| EBITDA | -341.35M |
| EBIT | -343.01M |
| Earnings Per Share (EPS) | -5.15 |
Balance Sheet
The company has $176.05M in cash and $7.06M in debt, giving a net cash position of $169.00M.
| Cash & Cash Equivalents | 176.05M |
| Total Debt | 7.06M |
| Net Cash | 169.00M |
| Retained Earnings | -895.03M |
| Total Assets | 608.88M |
| Working Capital | 364.50M |
Cash Flow
In the last 12 months, operating cash flow was -$222.79M and capital expenditures -$7.38M, giving a free cash flow of -$230.18M.
| Operating Cash Flow | -222.79M |
| Capital Expenditures | -7.38M |
| Free Cash Flow | -230.18M |
| FCF Per Share | -3.65 |
Margins
Gross margin is 92.25%, with operating and profit margins of -6.30K% and -5.97K%.
| Gross Margin | 92.25% |
| Operating Margin | -6.30K% |
| Pretax Margin | -5.97K% |
| Profit Margin | -5.97K% |
| EBITDA Margin | -6.27K% |
| EBIT Margin | -6.30K% |
| FCF Margin | -4.23K% |
Dividends & Yields
SWTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.42% |
| FCF Yield | -8.06% |
Analyst Forecast
The average price target for SWTX is $68, which is 77.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $68 |
| Price Target Difference | 77.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 20.12 |
| Piotroski F-Score | 3 |